Prostate Cancer Clinical Trials in Illinois

Showing 221-240 of 282 trials

Tivantinib in Treating Patients With Metastatic Prostate Cancer

NCT01519414

This randomized phase II trial studies how well tivantinib works compared to placebo in treating patients with metastatic prostate cancer. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Hormone-Resistant Prostate CancerProstate AdenocarcinomaRecurrent Prostate Carcinoma+1 more

National Cancer Institute (NCI)78 participantsStarted Jan 2012

Washington D.C., District of Columbia, United States • Tampa, Florida, United States • Chicago, Illinois, United States +17 more locations

COMPLETEDPhase 240 miles

Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate

NCT00006214

RATIONALE: Chemoprevention therapy is the use of certain drugs such as flutamide to try to prevent the development of cancer. Flutamide may be effective in the prevention of prostate cancer. PURPOSE: Randomized clinical trial to study the effectiveness of flutamide in preventing prostate cancer in patients who have neoplasia of the prostate.

Prostate Cancer

Alliance for Clinical Trials in Oncology63 participantsStarted Aug 2000

Scottsdale, Arizona, United States • Peoria, Illinois, United States • Urbana, Illinois, United States +20 more locations

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate

Prostate Cancer Trials in Other Cities

Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer

Abiraterone Post Ketoconazole for Prostate Cancer

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis

Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial

Health-Related Quality of Life in Gay Men With Localized Prostate Cancer

Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer

An Open-label Extension Study of PSMA ADC 2301 in mCRPC

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

Other Conditions in Illinois